Maynard Um
-
-
-
-
-
-
-
Eli Lilly's orforglipron outperforms oral semaglutide in diabetes trial
-
-
-
-
-
-
-
Eli Lilly launches multi-dose KwikPen for Zepbound weight management drug
-
-
-
-
-
-
-
This pharma stock is 'poised to outperform in 2026,' Wolfe says
-
-
-
-
-
-
-
Eli Lilly & Co. (LLY) call put ratio 1.3 calls to 1 put
-
-
-
-
-
-
-
Wells Fargo on Eli Lilly (LLY): 'Compounders Strike Again, but We See Little Risk to Near-Term Growth'
-
-
-
-
-
-
-
Eli Lilly (LLY) PT Raised to $1,260 at Goldman Sachs
-
-
-
-
-
-
-
Eli Lilly earnings preview Q4: strong print expected on obesity drugs demand
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

